Join        Login             Stock Quote

Ariad Sets The Ball Rolling For Blockbuster Drug

 December 17, 2012 01:03 PM

(By Mani) Ariad Pharmaceuticals Inc.'s (NASDAQ: ARIA) approval of ponatinib (Iclusig) is a major achievement that should set the company on the road to commercializing a long-term blockbuster drug.

Ponatinib is indicated for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior TKI therapy.

The good news is the labeled indication is very broad and requires only failure/intolerant to a prior drug. If Ariad's claim is to be believed, about 5,000 new cases of CML are diagnosed each year in the U.S., and patients treated with TKIs can develop resistance or intolerance over time to these therapies.

[Related -Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA): Rocking and Rolling on Iclusig]

However, there are concerns on warnings for arterial thrombosis and liver toxicity that can lead to dose reduction and/or discontinuation. However, one should note that the label includes all adverse events in the single arm trial, where it is impossible to delineate which are directly attributable to the drug, especially in these heavily pre-treated patients.

"We think launch will be fine and meet expectations due to a large prevalence pool, and ‘113 data at ASCO should be a positive catalyst," RBC Capital Markets analyst Michael Yee wrote in a note to clients.

[Related -Stocks Retreat On Apple (AAPL), 'Cliff' Concerns]

The oncology company commented that event rates drop by 50 percent in earlier line patients. Moreover, Novartis' Tasigna, which has a black box for Quantum Tunneling Composite (QTc) and sudden death, is a blockbuster drug, and box warning has not stopped its significant utilization despite lower efficacy than ponatinib. QTc is nothing but a measurement of a portion of heartbeat.

"Long term thinking on ponatinib unchanged: very high efficacy supports use in the broad population, and for an oncology indication, efficacy is key and physicians we spoke to are comfortable with the safety profile of the drug," Yee noted.

In addition, liver function tests such as ALTs (alanine aminotransferase) and ASTs (aspartate aminotransferase) are comparable to other TKIs, and Ponatinib has no QTc effects, unlike Tasigna.

"We believe the labeling is unlikely to affect physician adoption, or enrollment rates for EPIC (first line trial vs Gleevec), which we note has an interim at 50% enrollment completion, potentially putting data YE:13 or H1:14 (and should show perceived safety concerns today aren't real issues)," Yee noted.

The drug is being priced at $9580 for one month or Wholesale Acquisition Cost of $115,000, and would be with distributors in 2 weeks, and marketing materials approved in next 45 -60 days.

"With approval 3 months early, (we model only 40 of 100 early access patients, so more will be upside), we believe launch will meet/beat 2013 cons est of $37-$40M (US)," Yee added.

Ariad's approach to structure-based drug design has led to three internally discovered, molecularly targeted product candidates for drug-resistant and difficult-to-treat cancers, including certain forms of chronic myeloid leukemia, soft tissue and bone sarcomas, and non-small cell lung cancer. Ariad's primary value driver is ponatinib for the treatment of CML. The company is also partnered with Merck on ridaforolimus for sarcomas.



Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageAutomating Ourselves To Unemployment

In this current era of central planning, malincentives abound. We raced to frack as fast we could for the read on...

article imageFed: Waiting For June… Or Godot?

The Federal Reserve left interest rates unchanged yesterday, as widely expected. But the possibility of a read on...

article imageThe Single Best Place To Invest Your Money For Retirement

It was never supposed to be this daunting. At least that's what we were read on...

article imageNegative Blowback From Negative Interest Rates

The Federal Reserve is widely expected to leave interest rates unchanged today. But perhaps standing pat read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.